Cargando…
Anti-tumoral efficacy of therapeutic human anti-KIR antibody (Lirilumab/BMS-986015/IPH2102) in a preclinical xenograft tumor model
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991278/ http://dx.doi.org/10.1186/2051-1426-1-S1-P40 |
| _version_ | 1782312407268327424 |
|---|---|
| author | Sola, Caroline Chanuc, Fabien Thielens, Ariane Fuseri, Nicolas Morel, Yannis Bléry, Mathieu André, Pascale Vivier, Eric Graziano, Robert Romagne, Francois Bonnafous, Cécile |
| author_facet | Sola, Caroline Chanuc, Fabien Thielens, Ariane Fuseri, Nicolas Morel, Yannis Bléry, Mathieu André, Pascale Vivier, Eric Graziano, Robert Romagne, Francois Bonnafous, Cécile |
| author_sort | Sola, Caroline |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-3991278 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2013 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-39912782014-05-05 Anti-tumoral efficacy of therapeutic human anti-KIR antibody (Lirilumab/BMS-986015/IPH2102) in a preclinical xenograft tumor model Sola, Caroline Chanuc, Fabien Thielens, Ariane Fuseri, Nicolas Morel, Yannis Bléry, Mathieu André, Pascale Vivier, Eric Graziano, Robert Romagne, Francois Bonnafous, Cécile J Immunother Cancer Poster Presentation BioMed Central 2013-11-07 /pmc/articles/PMC3991278/ http://dx.doi.org/10.1186/2051-1426-1-S1-P40 Text en Copyright © 2013 Sola et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Poster Presentation Sola, Caroline Chanuc, Fabien Thielens, Ariane Fuseri, Nicolas Morel, Yannis Bléry, Mathieu André, Pascale Vivier, Eric Graziano, Robert Romagne, Francois Bonnafous, Cécile Anti-tumoral efficacy of therapeutic human anti-KIR antibody (Lirilumab/BMS-986015/IPH2102) in a preclinical xenograft tumor model |
| title | Anti-tumoral efficacy of therapeutic human anti-KIR antibody (Lirilumab/BMS-986015/IPH2102) in a preclinical xenograft tumor model |
| title_full | Anti-tumoral efficacy of therapeutic human anti-KIR antibody (Lirilumab/BMS-986015/IPH2102) in a preclinical xenograft tumor model |
| title_fullStr | Anti-tumoral efficacy of therapeutic human anti-KIR antibody (Lirilumab/BMS-986015/IPH2102) in a preclinical xenograft tumor model |
| title_full_unstemmed | Anti-tumoral efficacy of therapeutic human anti-KIR antibody (Lirilumab/BMS-986015/IPH2102) in a preclinical xenograft tumor model |
| title_short | Anti-tumoral efficacy of therapeutic human anti-KIR antibody (Lirilumab/BMS-986015/IPH2102) in a preclinical xenograft tumor model |
| title_sort | anti-tumoral efficacy of therapeutic human anti-kir antibody (lirilumab/bms-986015/iph2102) in a preclinical xenograft tumor model |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991278/ http://dx.doi.org/10.1186/2051-1426-1-S1-P40 |
| work_keys_str_mv | AT solacaroline antitumoralefficacyoftherapeutichumanantikirantibodylirilumabbms986015iph2102inapreclinicalxenografttumormodel AT chanucfabien antitumoralefficacyoftherapeutichumanantikirantibodylirilumabbms986015iph2102inapreclinicalxenografttumormodel AT thielensariane antitumoralefficacyoftherapeutichumanantikirantibodylirilumabbms986015iph2102inapreclinicalxenografttumormodel AT fuserinicolas antitumoralefficacyoftherapeutichumanantikirantibodylirilumabbms986015iph2102inapreclinicalxenografttumormodel AT morelyannis antitumoralefficacyoftherapeutichumanantikirantibodylirilumabbms986015iph2102inapreclinicalxenografttumormodel AT blerymathieu antitumoralefficacyoftherapeutichumanantikirantibodylirilumabbms986015iph2102inapreclinicalxenografttumormodel AT andrepascale antitumoralefficacyoftherapeutichumanantikirantibodylirilumabbms986015iph2102inapreclinicalxenografttumormodel AT viviereric antitumoralefficacyoftherapeutichumanantikirantibodylirilumabbms986015iph2102inapreclinicalxenografttumormodel AT grazianorobert antitumoralefficacyoftherapeutichumanantikirantibodylirilumabbms986015iph2102inapreclinicalxenografttumormodel AT romagnefrancois antitumoralefficacyoftherapeutichumanantikirantibodylirilumabbms986015iph2102inapreclinicalxenografttumormodel AT bonnafouscecile antitumoralefficacyoftherapeutichumanantikirantibodylirilumabbms986015iph2102inapreclinicalxenografttumormodel |